Mol, I., Hu, Y., LeBlanc, T. W., Cappelleri, J. C., Chu, H., Nador, G., … Hlavacek, P. (2024). Updated Results of a Matching-Adjusted Indirect Comparison of Elranatamab Versus Teclistamab in Patients with Triple-Class Exposed/Refractory Multiple Myeloma. In Blood (Vol. 144, pp. 3367–3367). American Society of Hematology. https://doi.org/10.1182/blood-2024-206951

Mol, Isha, Yannan Hu, Thomas W. LeBlanc, Joseph C. Cappelleri, Haitao Chu, Guido Nador, Didem Aydin, Isabel Perez-Cruz, and Patrick Hlavacek. “Updated Results of a Matching-Adjusted Indirect Comparison of Elranatamab Versus Teclistamab in Patients with Triple-Class Exposed/Refractory Multiple Myeloma.” In Blood, 144:3367–3367. American Society of Hematology, 2024. https://doi.org/10.1182/blood-2024-206951.

Mol I, Hu Y, LeBlanc TW, Cappelleri JC, Chu H, Nador G, et al. Updated Results of a Matching-Adjusted Indirect Comparison of Elranatamab Versus Teclistamab in Patients with Triple-Class Exposed/Refractory Multiple Myeloma. In: Blood. American Society of Hematology; 2024. p. 3367–3367.

Mol, Isha, et al. “Updated Results of a Matching-Adjusted Indirect Comparison of Elranatamab Versus Teclistamab in Patients with Triple-Class Exposed/Refractory Multiple Myeloma.” Blood, vol. 144, no. Supplement 1, American Society of Hematology, 2024, pp. 3367–3367. Crossref, doi:10.1182/blood-2024-206951.

Mol I, Hu Y, LeBlanc TW, Cappelleri JC, Chu H, Nador G, Aydin D, Perez-Cruz I, Hlavacek P. Updated Results of a Matching-Adjusted Indirect Comparison of Elranatamab Versus Teclistamab in Patients with Triple-Class Exposed/Refractory Multiple Myeloma. Blood. American Society of Hematology; 2024. p. 3367–3367.